

Supplementary Data

Long-Term Effects of Galantamine on Cognitive Function in Alzheimer's Disease: A Large-Scale International Retrospective Study

Shane Kavanagh^{a,*}, Bart Van Baelen^b and Barbara Schäuble^c

^a*Janssen Global Services, Beerse, Belgium*

^b*SGS Life Science Services, Mechelen, Belgium*

^c*Janssen-Cilag Medical Affairs, Neuss, Germany*


Accepted 6 July 2011

Supplementary Table 1
Reasons for trial discontinuation

Exposure to galantamine	Number (%) ¹ of patients completing	Number (%) ¹ of patients discontinuing for a given reason ²						
		Adverse event	Death	Ineligible to continue	Insufficient response	Non-compliance	Withdrew consent	Other
None	11 (42.3)	9 (34.6)	0	0	1 (3.8)	2 (7.7)	0	3 (11.5)
>0–6 months	11 (10.3)	80 (74.8)	0	1 (0.9)	2 (1.9)	4 (3.7)	1 (0.9)	8 (7.5)
>6–12 months	16 (42.1)	15 (39.5)	1 (2.6)	0	0	1 (2.6)	3 (7.9)	1 (2.6)
>1–2 years	27 (45.8)	14 (23.7)	9 (15.3)	0	3 (5.1)	1 (1.7)	3 (5.1)	2 (3.4)
>2–3 years	43 (61.4)	10 (14.3)	3 (4.3)	0	2 (2.9)	4 (5.7)	2 (2.9)	6 (8.6)
>3 years	170 (95.5)	2 (1.1)	0	0	2 (1.1)	1 (0.6)	0	3 (1.7)
Total	278 (58.2)	130 (27.2)	13 (2.7)	1 (0.2)	10 (2.1)	13 (2.7)	9 (1.9)	23 (4.8)

¹The denominator is the number of patients within a treatment exposure subgroup. ²One patient who received galantamine treatment for >6–12 months discontinued, but the reason for this was not specified.

*Correspondence to: Shane Kavanagh, Janssen Global Services, 30 Turnhoutseweg, 2340 Beerse, Belgium. Tel.: +32 14607455; Fax: +32 14605425; E-mail: skavanag@its.jnj.com.



Supplementary Figure 1. Observed changes in Mini-Mental State Examination (MMSE) scores over time. A) Changes during galantamine therapy ($n=171$). B) Changes after withdrawing from galantamine ($n=89$).